Telix Launches First Asia-Pacific Cyclotron Facility in Japan, Hosts Nuclear medicine Lecture
Yokohama, Japan – November 21, 2025 – Telix today announced the opening of Telix manufacturing Solutions (TMS) Yokohama, its first cyclotron facility in the Asia-Pacific (APAC) region. The new facility, located in Yokohama, Japan, will increase access to radiopharmaceuticals for patients in Japan, beginning with the clinical supply of TLX250-CDx, an imaging agent for kidney cancer.
Telix plans to expand TMS YokohamaS capabilities to include the supply of other investigational and future commercial products, encompassing precision diagnostics and therapies for prostate and brain cancers, pending regulatory approvals.
The opening was marked by a commemorative lecture delivered by Professor Jun Hatazawa, Vice President of the Japan Isotope Association and Professor of the Next-Generation Cancer Therapy Research division at Osaka University. Professor Hatazawa’s lecture was titled: ‘Trends and Challenges for the Future of Nuclear Medicine’.
Raphael Ortiz, CEO International Business and Japan President at Telix, highlighted the significance of the launch. “The opening of TMS Yokohama is a important milestone for Telix as it enhances our capacity to meet growing demand for radiopharmaceuticals in Japan and Asia Pacific. As the world’s second-largest nuclear medicine market, we have always considered Japan a key country in our clinical and commercial strategy. today demonstrates our commitment to the Japanese community, to scientific excellence, and to the well-being of patients throughout the region.”
TMS is Telix’s global network of 39 manufacturing and distribution facilities spanning five continents. Thes facilities support the production and delivery of both clinical and commercial radiopharmaceutical doses worldwide. Capabilities include isotope production, translational research, radiochemistry, antibody engineering, bioconjugation, and finished radiopharmaceutical manufacturing and distribution. Telix notes its TMS Brussels South site, with nine GMP lines and two cyclotrons across 30,000 sq ft, is one of Europe’s largest radiopharmaceutical production facilities, and its RLS network in the United States delivers over 2.5 million patient doses annually. The company’s ARTMS QUANTM Irradiation System® (QIS®) technology will be deployed at TMS Yokohama, alongside select RLS radiopharmacies and TMS Brussels South.
